Sorafenib is effective in the treatment of pulmonary veno-occlusive disease

Masaharu Kataoka, Ryoji Yanagisawa, Keiichi Fukuda, Hideaki Yoshino, Toru Satoh

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


The present study is the first report of the effectiveness of sorafenib in the treatment of pulmonary veno-occlusive disease (PVOD). A 66-year-old woman with PVOD was started on sorafenib. After 3 months of treatment with a maximum dosage of 400 mg/day sorafenib, there was an improvement in the patient's New York Heart Association (NYHA) functional class from IV to III. However, because of severe painful eruptions as a side effect of sorafenib, the patient stopped sorafenib and was started on imatinib instead. This treatment resulted in a worsening of the patient's NYHA class from III to IV, so sorafenib was restarted at a reduced dosage of 300 mg/day. The resumption of sorafenib was associated with clinical improvement, specifically NYHA class from IV to II and hemodynamic amelioration, and tolerable eruptions. In conclusion, sorafenib may be a potential therapeutic strategy for the treatment of PVOD.

Original languageEnglish
Pages (from-to)172-174
Number of pages3
JournalCardiology (Switzerland)
Issue number3
Publication statusPublished - 2012 Nov
Externally publishedYes


  • Hypertension
  • Imatinib
  • Pulmonary veno-occlusive disease
  • Side effect
  • Sorafenib

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Sorafenib is effective in the treatment of pulmonary veno-occlusive disease'. Together they form a unique fingerprint.

Cite this